Last Updated on May 26, 2026
⚠️ 2026 update on CGRP medications for migraine
This media segment is from 2021, when Emgality had just become PBS-listed and the other CGRP options were still on a private prescription. The landscape has changed significantly. In 2026:
- 3 CGRP medications are PBS-listed in Australia: Emgality (galcanezumab), Ajovy (fremanezumab) and Vyepti (eptinezumab — IV).
- Aimovig (erenumab) is registered in Australia but is not PBS-subsidised; full private cost applies.
- PBS criteria require chronic migraine with ≥8 headache days per month, failed ≥3 oral preventatives, neurologist prescription, and not concurrently on PBS Botox.
For the current 2026 picture, please read: CGRP Medications for Migraine in 2026 — Emgality, Ajovy, Vyepti and Aimovig — or visit Sydney Headache Centre — CGRP therapies.
With the PBS approval of Emgality, Dr Granot was also featured on radio 2GB news regarding chronic migraine and Emgality. Click below to listen to the news segment.
The key points to remember about Chronic Migraine therapy is the importance of preventative therapy, something taken regularly to reduce the frequency and severity of each migraine attack, but also combined with lifestyle management and trigger management.
Emgality is an important and well tolerated addition to the numerous other therapies we have to treat migraine, including Botox 3 monthly injections.
The key takeaway is that there are lots of successful therapies available. Lots of things to try.